At CC Diagnostics, we aim to improve the detection of cervical cancer. We are developing a PCR-based reagent kit that provides accurate and timely results, ensuring early intervention and better patient outcomes.
Our cutting-edge technology allows for the early detection of cervical cancer, providing patients with a higher chance of successful treatment. With our innovative approach, we can identify abnormalities at the earliest stage, ensuring timely intervention and improved outcomes.
Despite screening programs being widely available, cervical cancer goes largely undetected, leading to high morbidity and mortality. There is a global inequity in access to screening and treatment.
CC Diagnostics
At CC Diagnostics, we believe that early detection is key to improving patient outcomes. Our innovative medical advances are revolutionizing cervical cancer detection, providing accurate and timely results that can save lives.
Traditional screening typically involves a primary HPV test and, if positive, a subsequent Pap smear. For the Pap smear, the gynecologist takes a cervical scraping which is then analyzed by a technician under the microscope.
Pap smears are analyzed subjectively under the microscope, risking human error.
The cervical scraping collection is painful and creates both emotional and physical barriers, leading to only 15% global participation in screening programs
Pap smears require more manual processing and are not compatible with automation. Each 4-week delay in diagnosis results in a 10% increase in mortality.
Our Solution
A PCR assay for cervical cancer screening using novel biomarkers.
* Product in development, not available for clinical use. Performance demonstrated in internal evaluations
Molecular assays like the HPV test have already revolutionized screening once, introducing benefits like self-sampling for patients, automation for clinicians, and improved cost-effectiveness for payers. With fully molecular screening via HPV testing and Methica CC triage, everone would benefit.
Less waiting. More certainty. More comfort.
Test up to 94 samples simultaneously. Improved patient management.
More cancers detected = less spending on treatments. Up to €700M saved.
Event
🌟**Nutte van Belzen MD** had the immense pleasure to share the stage with three other startups and pitch for the award during the LIFE Science Conference in Groningen.
Accelerator
🤩 This is a golden opportunity in Los Angeles! CC Diagnostics got selected to participate in the HealthTech Mini-Accelerator, a tailor-made program exclusively for Dutch HealthTech startups. This program is a collaborative effort between Cedars-Sinai Accelerator, NBSO Los Angeles and ScaleNL.
Clinical Study
CC Diagnostics has successfully completed a large clinical validation study using samples from the Dutch National Screening Program. The results? 97% sensitivity for cancer detection, outperforming the pap smear by 21%—all without compromising specificity. This study, conducted across multiple centers, reflects real-world performance and eliminates bias, marking a significant leap forward in cervical cancer diagnostics.